HOME >> MEDICINE >> NEWS
Drivers with epilepsy are on the road again

As a result of a worldwide cooperative movement, the absolute driving ban for people with epilepsy (PWE) has been lifted in Japan. Since 1960, people who have epilepsy have been banned from driving in Japan. A December article in the journal Epilepsia outlines the efforts and procedures taken to reinstate driving rights to people with epilepsy, a restriction affecting many epilepsy patients throughout the world.

According to experts at Johns Hopkins University, 86 drivers per year died in the U.S. as a result of crashes caused by epileptic seizures between 1995 and 1997. With this potential for accidents and fatalities, laws have been put in place to restrict people who have epilepsy from operating vehicles. Similar restrictions exist for persons with progressive vision loss, for example, reserving the privilege for those who are less likely to have an accident.

A draft of the Road Traffic Act in Japan in December of 2000 stated that people who suffer from epilepsy would not be eligible to receive a driving license at all. After protests from local and international epilepsy organizations and individuals, the Act was revised to allow PWE to obtain a driving license after a seizure-free period of two years.

In order to survey the effect of these new driving regulations, questionnaires were sent to driving authorities and doctors of the Japanese Epilepsy Society (JES). Data showed that some PWE were unwilling to declare their conditions for fear of losing a job, or having their licenses eventually taken away.

"The survey results [further] highlighted the need for cooperation between the driving authorities and JES for further amendment of the regulations as well as the importance of education for the public, patients and professionals," states lead author Yushi Inoue, MD, PhD. These are key factors in efforts to modify restrictions for PWE driving rights worldwide.

According to Dr. Inoue, there are several countries
'"/>

Contact: Sharon Agsalda
medicalnews@bos.blackwellpublishing.net
781-388-8507
Blackwell Publishing Ltd.
23-Dec-2004


Page: 1 2

Related medicine news :

1. Drivers with type-1 diabetes report increased incidence of car crashes
2. New studies show mixed results on epilepsy drugs and birth defects
3. Controversial Atkins Diet may be beneficial for people with epilepsy
4. Early seizures after epilepsy surgery predict more seizures
5. Pacemakers could protect patients with epilepsy from sudden unexplained death
6. Technology points to possible targets for epilepsy and Alzheimers drugs
7. Mayo Clinic finds ketogenic diet may be started as an outpt treatment for children with epilepsy
8. American Academy of Neurology guidelines for treating of epilepsy
9. Monthly hormonal changes can exacerbate seizures in women with epilepsy
10. Patients with uncontrolled epilepsy have low levels of fatty acids
11. Surgery for treatment of temporal lobe epilepsy varies among ethnic groups

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Drivers with epilepsy are the road again

(Date:4/17/2014)... signs of chronic inflammation in non-cancerous prostate tissue may ... cancer than those with no inflammation, according to results ... Johns Hopkins Kimmel Cancer Center. , The link between ... with so-called high-grade prostate cancer those with a ... presence of the most aggressive and rapidly growing prostate ...
(Date:4/17/2014)... a study published today in PLOS Pathogens , ... malaria is common can mount an immune response to ... avoid repeated bouts of high fever and illness and ... bloodstream. The findings may help researchers develop future interventions ... malaria parasite. , Each year, approximately 200 million cases ...
(Date:4/17/2014)... In a review published in the April issue of ... The Feinstein Institute for Medical Research, says it,s time ... approach to treating sepsis, which kills millions ... Sepsis occurs when molecules released into the bloodstream to ... body. Inflammation is necessary for maintaining good health ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
(Date:4/17/2014)... By discovering a new mechanism that allows blood to ... UC Irvine and the Salk Institute have opened the ... stroke-induced brain damage. , A complex and devastating neurological ... primary reason for disability in the U.S. The blood-brain ... blood-borne material into the brain, causing the permanent deficits ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... 2014 HeartWare International, Inc . (NASDAQ: ... miniaturized circulatory support technologies that are revolutionizing the treatment ... revenues for the fourth quarter of 2013 will be ... approximately $208 million. "Our full-year revenue growth ...
(Date:1/14/2014)... 14, 2014 InformEx, North America,s ... chemistry, will hold the 30 th edition of its ... Convention Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ... pharmaceutical, fine chemical and specialty chemical companies will take part ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
Cached News: